Breaking News

PBS Biotech Scales-Up Manufacturing Solutions for Cell Therapies

Raises $10 million to grow its product offerings and capabilities.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Single-use bioreactor manufacturer, PBS Biotech, recently closed a private $10 million funding round with BroadOak Capital Partners. The financing will enable the company to expand and industrialize its portfolio of single-use bioreactor systems and contract process development services.   “Cell therapies represent a paradigm shift that enable durable cures for today’s untreatable diseases. PBS Biotech is well-positioned to enable scalable manufacturing of stem cells in this emerging space, and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters